Unity Confirm uses fetal cell capture

This shifts BillionToOne from front end screening into a second, higher value decision point where doctors need more certainty without sending a patient to an invasive procedure. UNITY Screen reads tiny fetal DNA fragments floating in maternal blood, while Unity Confirm tries to pull out whole intact fetal cells, then sequence each cell across the whole genome. That gives BillionToOne a way to sell a follow on test after a high risk screen, using the same OB workflow and the same maternal blood draw.1 3 4 5

• Most prenatal screens from companies like Natera are cfDNA tests. They look at fragmented DNA in maternal blood and estimate risk statistically. Unity Confirm is different because it isolates rare circulating fetal cells first, which BillionToOne says effectively gives full fetal fraction for each captured cell before sequencing.3 4 5
• In practice, this is aimed at the gap after a positive aneuploidy screen and before CVS or amniocentesis. BillionToOne launched Unity Confirm in May 2026 for patients with high risk UNITY Aneuploidy results, covering trisomy 21, 18, 13, 22q11.2 microdeletion, and some sex chromosome aneuploidies before 16 weeks.3 5 6
• The business implication is incremental revenue from an existing patient flow rather than a brand new market. BillionToOne already built adoption with a one tube prenatal screen that does not require paternal samples. Unity Confirm adds a second reimbursable test for the subset of pregnancies that need confirmation, without requiring new clinic relationships.1 6

The next step is proving this works at scale, then turning fetal cell capture into a durable wedge against standard cfDNA competitors. If larger studies hold up, BillionToOne can own more of the prenatal pathway, from first screen to non invasive confirmation, and make its OB account base materially more valuable.1 3 5